Table 2.
Baseline demographics and clinical characteristics
| Characteristic | Roxadustat (N = 444) |
|---|---|
| Age (years), mean (SD) | 64.2 (11.7) |
| Sex (male), n (%) | 291 (65.5) |
| Dialysis vintage (months), mean (SD) | 69.1 (80.2) |
| Dialysis vintage, n (%) | |
| ≤ 4 months | 83 (18.7) |
| > 4 months | 361 (81.3) |
| History of diabetes, n (%) | 166 (37.4) |
| History of thromboembolism, n (%) | 115 (25.9) |
| History of cardiovascular disease, n (%) | 62 (14.0) |
| Body mass index (kg/m2), mean (SD) | 22.8 (3.7) |
| Previous ESA treatment, n (%) | |
| Naive | 88 (19.8) |
| Conversion | 356 (80.2) |
| Concomitant antiplatelet agent use, n (%) | 202 (45.5) |
| Concomitant anticoagulant use, n (%) | 18 (4.1) |
| Concomitant IV or oral iron therapy use (including ferric citrate), n (%) | 265 (59.7) |
| Concomitant IV iron therapy use, n (%) | 110 (24.8) |
| Concomitant oral iron therapy use (including ferric citrate), n (%) | 173 (39.0) |
| Hemoglobin at week 0 (g/dL), mean (SD) | 10.5 (1.2) |
| Ferritin at week 0 (ng/mL), median (min, max) | 90.8 (6.9, 572.0) |
| TSAT at week 0 (%), mean (SD) | 29.9 (11.9) |
| Transferrin at week 0 (g/L), median (min, max) | 1.8 (0.9, 3.3) |
| Platelets at week 0 (104/µL), mean (SD) | 20.5 (6.3) |
| hsCRP at week 0 (mg/dL), median (min, max) | 0.06 (0.0, 6.3) |
ESA erythropoiesis-stimulating agent, hsCRP high-sensitivity C-reactive protein, max maximum, min minimum, SD standard deviation, TSAT transferrin saturation